cbdMD, Inc.
YCBD Healthcare Drug Manufacturers Specialty & Generic
cbdMD, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $19.2 million, down 1.50% from fiscal 2024. In the quarter to June 2026, revenue grew 20.6%, EPS grew 47.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
Follow YCBD
cbdMD, Inc. (YCBD) EV/Sales
As of 16 October 2026, cbdMD, Inc. (YCBD) trades at a EV/Sales of 0.2×. Over the past ten years it has ranged from 0.0× (October 2023) to 186× (February 2019); the current reading is higher than 25% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.3× | 156.99% |
| FY2024 | 0.1× | 84.06% |
| FY2023 | 0.1× | (71.59%) |
| FY2022 | 0.2× | (90.17%) |
| FY2021 | 2.0× | 10.60% |
| FY2020 | 1.8× | (36.34%) |
| FY2019 | 2.8× | (96.83%) |
| FY2018 | 88.6× | 1,481.32% |
| FY2017 | 5.6× | 0.00% |
| FY2016 | 5.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.4× | (5.76%) |
| Mar 2026 | 0.4× | (35.90%) |
| Dec 2025 | 0.6× | 124.13% |
| Sep 2025 | 0.3× | (23.50%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNOA Sonoma Pharmaceuticals, Inc. compare | 0.0× |
| GELS Gelteq Limited compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| YCBD cbdMD, Inc. | 0.2× |
| INM InMed Pharmaceuticals Inc. compare | 0.6× |
| RDHL Redhill Biopharma Ltd. compare | 6.4× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)